All In Biotech

Drug Trial Radar · NCT05480436

Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population

Immunogenicity and Safety of Inactivated COVID-19 Vaccine Coadministered With 23-valent Pneumococcal Polysaccharide Vaccine and Quadrivalent Influenza Vaccine in Hemodialysis Population: a Multicentre, Randomised, Controlled, Phase 4 Trial

Last checked: Nov 19, 2026Latest source record: Aug 30, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,200

Planned (sponsor's estimate)

Start

Aug 5, 2022

Primary completion

Jan 30, 2023

Study completion Jul 30, 2023

Sponsor

Sponsor type
Industry
Collaborators
Hunan Provincial Center for Disease Control and Prevention; Sichuan Center for Disease Control and Prevention; Guizhou Center for Disease Control and Prevention; Xiangya Hospital of Central South University; Beijing Institute of Biological Products Co Ltd.; Chengdu Institute of Biological Products Co.,Ltd.; Shanghai Institute Of Biological Products
First posted
Jul 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluation of immunogenicity and safety of inactivated COVID-19 vaccine (BBIBP-Corv) coadministered with PPV23 and IIV4 in hemodialysis population.

Conditions

  • Hemolysis
  • COVID-19

Interventions

  • coadministrationBiological

    the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and IIV4 on Day 0, and the coadministration of BBIBP-CorV and PPV23 on Day 28

  • COVID-19 vaccineBiological

    received two doses of inactivated COVID-19 vaccine (BBIBP-CorV)

  • IIV4+PPV23Biological

    received one dose of IIV4 on Day 0, and one dose of PPV23 on Day 28

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Seroconversion rate against SARS-CoV-2Time frame: 28 days after two doses vaccination (Day 56)
  2. Seroconversion rate against IIV4Time frame: 28 days after vaccination (Day 28)
  3. Seroconversion rate against PPV23Time frame: 28 days after vaccination (Day 56)
  4. Neutralizing antibody GMT against SARS-CoV-2Time frame: 28 days after two doses vaccination (Day 56)
  5. Hemmagglution inhibition antibody GMT against IIV4Time frame: 28 days after vaccination (Day 28)
  6. IgG antibody GMC against PPV23Time frame: 28 days after vaccination (Day 56)
  7. Neutralizing antibody geometric mean increase (GMI) against SARS-CoV-2Time frame: 28 days after two doses vaccination (Day 56)
  8. Hemmagglution inhibition antibody GMI against IIV4Time frame: 28 days after vaccination (Day 28)
  9. IgG antibody GMI against PPV23Time frame: 28 days after vaccination (Day 56)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Xiangya Hospital Central South University

    Changsha, China · Not yet recruiting

  • Sichuan Center for Disease Control and Prevention

    Chengdu, China · Recruiting

  • Guizhou Center for Disease Control and Prevention

    Guiyang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.